Tolvaptan News and Research

RSS
Tolvaptan is a vasopressin V2 receptor blocker that shows promise for management of heart failure.
Promising new drug being developed for polycystic kidney disease

Promising new drug being developed for polycystic kidney disease

Scientists develop new class of drugs to treat hereditary kidney disease

Scientists develop new class of drugs to treat hereditary kidney disease

Otsuka’s JINARC approved for treatment of patients with CKD stage 4 ADPKD

Otsuka’s JINARC approved for treatment of patients with CKD stage 4 ADPKD

Research reveals long-term efficacy of drug used to treat common cause of kidney failure

Research reveals long-term efficacy of drug used to treat common cause of kidney failure

Mild reduction in food intake slows development of autosomal-dominant polycystic kidney disease

Mild reduction in food intake slows development of autosomal-dominant polycystic kidney disease

JINARC (tolvaptan) accepted for use in Scotland for ADPKD treatment

JINARC (tolvaptan) accepted for use in Scotland for ADPKD treatment

First European approval of drug to treat genetic kidney disease ADPKD

First European approval of drug to treat genetic kidney disease ADPKD

EMA's CHMP backs JINARC (tolvaptan) for autosomal dominant polycystic kidney disease

EMA's CHMP backs JINARC (tolvaptan) for autosomal dominant polycystic kidney disease

Discovery reveals promising target for treatment of end-stage heart failure

Discovery reveals promising target for treatment of end-stage heart failure

Otsuka Pharmaceutical begins tolvaptan Phase 3b study in patients with ADPKD

Otsuka Pharmaceutical begins tolvaptan Phase 3b study in patients with ADPKD

Otsuka obtains regulatory approval in Japan for pharmacological treatment of ADPKD

Otsuka obtains regulatory approval in Japan for pharmacological treatment of ADPKD

EMA accepts Otsuka's marketing authorisation application for tolvaptan for treatment of ADPKD

EMA accepts Otsuka's marketing authorisation application for tolvaptan for treatment of ADPKD

FDA accepts Otsuka Pharmaceutical's tolvaptan NDA for priority review

FDA accepts Otsuka Pharmaceutical's tolvaptan NDA for priority review

Tolvaptan improves kidney health in polycystic kidney disease

Tolvaptan improves kidney health in polycystic kidney disease

Study highlights potential treatment that reduces kidney growth

Study highlights potential treatment that reduces kidney growth

Tolvaptan shows promise in treating autosomal dominant polycystic kidney disease

Tolvaptan shows promise in treating autosomal dominant polycystic kidney disease

Health Canada issues notice of compliance for OCPI's SAMSCA to treat hyponatremia

Health Canada issues notice of compliance for OCPI's SAMSCA to treat hyponatremia

Critical follow-up evaluations provide opportunity to help physicians best evaluate their HF patients

Critical follow-up evaluations provide opportunity to help physicians best evaluate their HF patients

FDA approves Samsca (tolvaptan) to treat hyponatremia

FDA approves Samsca (tolvaptan) to treat hyponatremia

FDA approves Samsca tablets (tolvaptan) to treat hyponatremia

FDA approves Samsca tablets (tolvaptan) to treat hyponatremia